– Precision health startup Q Bio emerges out of stealth mode, raising $40M in Series B funding led by Andreessen Horowitz to bring preventative health and the physical of the future to masses.
– In 75 minutes or less, members are able to get a comprehensive picture of their health and receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians.
Q Bio, a Redwood City, CA-based quantitative, clinically relevant assessment of personal human health, announced it has officially come out of stealth mode and secured $40 million in Series B funding led by Andreessen Horowitz. The Series B funding round brings Q Bio’s total funding to $58 million.
Prevention is Better Than the Best Treatment
Today’s healthcare system is reactive to treat us when we are sick instead of being proactive. Founded in 2015, Q Bio wants to make it easier to identify signs of disease at the earliest stages, before symptoms arise — when intervention produces the best outcomes.
The company has spent the last few years in stealth mode, focused on fine-tuning its imaging protocols and determining the most clinically relevant set of over 3000 biomarkers to include in its platform that can look for existential risks in an asymptomatic population. In 75 minutes or less, members are able to get a comprehensive picture of their health and receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians.
Q Bio uses a systems biology approach called panomics to build a comprehensive, quantitative snapshot of your health by combining advanced non-invasive imaging, chemistry, genetics, vitals and your medical history. The Q Exam non-invasively measure thousands of biomarkers designed to detect changes associated with common cancers, cardiac, neurodegenerative, and metabolic diseases, as well as musculoskeletal issues, and exposure to environmental toxins.
The Q exam protocol is IRB approved and was designed and reviewed in collaboration with clinicians and researchers with the goal of identifying pathology at early stages across five categories of common existential risks.
After the exam is completed, the company provides members with a Q report, an easy-to-understand summary of the health of each of the member’s body systems, important changes in them, and how they affect your personal risk factors.
All of the information is stored on the Q BioValut that will continuously aggregate, digitize and index all of your records for up to one year after your most recent Q Exam. With each visit, Q adapts to the member’s changing risk factors in order to measure and highlight the things that matter most to their health.
The annual Q membership starts at $3,495 includes the aggregation of your personal medical history for one year, one Q Exam and Data Review, and lifetime access to your BioVault. Additional future Q Exams can be scheduled at a frequency that may be based on current and future health risks but is ultimately up to the member and their care provider. The membership cost is incurred for each Q Exam scheduled.
This latest round of funding will allow Q Bio to continue to improve its proprietary platform and technology to make its preventive health services faster, better and more affordable for all. The company quietly opened its doors to a limited membership in late 2019 and plans to open additional locations this year.
“Since my own misdiagnoses over a decade ago, I’ve imagined a day when everything about a person’s body could be quickly measured, shared and analyzed. It took time but Q Bio was born,” said Jeffrey Kaditz, co-founder and CEO of Q Bio. “We are thrilled to have our current investors continue to share our vision and excitement for what is possible in the field of preventive health.”